ArticleVeterinary research2025
Cav1.2 facilitates the binding and internalisation of porcine epidemic diarrhoea virus.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A novel TaqMan-based RT-qPCR assay for the detection of PEDV and discrimination of the G2c subtype.Archives of virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Porcine epidemic diarrhoea virus (PEDV) has caused substantial economic losses to the global swine industry. The PEDV spike (S) protein mediates viral entry by interacting with host receptors. However, the molecular mechanisms underlying PEDV entry remain incompletely understood. In this study, we identified the L-type calcium channel Cav1.2 as a critical host factor for PEDV entry. Depletion of Cav1.2 significantly suppressed PEDV replication. Additionally, treatment with the FDA-approved Cav1.2 blocker diltiazem inhibited PEDV replication and disrupted early infection events. Mechanistically, we found that Cav1.2 interacts with the PEDV S1 subunit. Both Cav1.2 knockdown and diltiazem treatment substantially reduced the binding and internalisation of PEDV. These findings reveal that Cav1.2 is a key host factor for PEDV binding and internalisation via interaction with the viral S protein, and suggest that Cav1.2 may serve as a promising target for antiviral drug development against PEDV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.